Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer Subjects in China

NCT05297890 is registered in ClinicalTrials.gov with CStone Pharmaceuticals as lead sponsor.

NCT NCT05297890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05297890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer Subjects in China
Lead sponsor
CStone Pharmaceuticals
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 27, 2022
Completion date
May 31, 2027
Enrollment
70 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic ros1-positive non-small cell lung cancer